Venclexta is an anti-cancer drug owned by Abbvie Inc. It was first authorized for market use on 11 April, 2016, and is available in oral tablet forms. The active ingredient in Venclexta is venetoclax. Currently, Venclexta holds nine drug patents, none of which have expired.
The last patent for Venclexta is expected to expire on 6 September, 2033. So, the generic version of Venclexta could become available in the market after this date.
Venclexta is used predominantly in the treatment of different forms of leukemia. It is effective in cases of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), for which it is combined with GA101 antibodies like obinutuzumab. It is also applied to treat acute myeloid leukemia (AML) in adults who are 75 years or older, or have specific comorbidities. The treatment plan often includes a dose ramp-up and it may be combined with other medicines like azacitidine, decitabine, or low-dose cytarabine.
Venclexta has a total of nine drug patents, with the last patent set to expire on 6 September, 2033. Upon this expiration, the Venclexta generic could become available. Below are the details of the patents: